The news organization cites a ProPublica website, Dollars for Docs, which shows that Gottlieb has received more than $400,000 from the pharmaceutical industry between August 2013 and December 2015 from promotional talks, research, consulting and travel during his time practicing at Stamform Hospital in CT.
Prior to joining the FDA, Dr Gottlieb was board director or advisor to several drug companies, including Tolero, GlaxoSmithKline, and Glytec Pharmeceuticals.
Donald Trump's pick to head the FDA, Scott Gottlieb, MD, is a former big pharma board member and investor in medical startups, according to reports, which could create conflicts of interest if he is confirmed. But while he delivered the comments with the bravado and populist rhetoric that have become the hallmark of his discourse, both in the public and on social media, he surprised a number of political and media observers alike when he announced on March 10, 2017 his intention to nominate Scott Gottlieb, MD, as the next commissioner of the FDA.
The nominee served as deputy commissioner of the agency under President George W. Bush.
Concerns regarding Gottlieb's fit and impartiality probably will come up at his Senate confirmation hearing, which could delay his confirmation, similar to what happened with his predecessor, Califf.
Devin Dunes Finally Gives Up on the Trump Tower Wiretap
In a series of tweets on March 4, Trump accused President Obama of wiretapping him and he urged Congress to investigate the claim. The two are leading one of three Congressional investigations into Russia's interference in the United States elections.
Rep. Rosa DeLauro, D-Conn., who serves on the House Appropriations subcommittee that oversees FDA funding, said Gottlieb's nomination sends the message that Trump is committed to "rolling back regulations and opening the floodgates to potentially unsafe drugs and medical devices", reports AP.
Gottlieb graduated from Mount Sinai School of Medicine and also studied Economics at Wesleyan University in Middletown, Connecticut. "If Dr. Gottlieb continues [with] the FDA on this path of lowering standards, insurance companies will do what they've already started to do, which is to say, 'We're just not going to automatically cover FDA products, because too many of them are being approved without proof that they worked'".
"When Gottlieb served as FDA deputy commissioner, he was recused from many key meetings and decisions due to his close relationship with industry".